Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo

Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We hypo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wright, Laura E., Harhash, Ahmed A., Kozlow, Wende M., Waning, David L., Regan, Jenna N., She, Yun, John, Sutha K., Murthy, Sreemala, Niewolna, Maryla, Marks, Andrew R., Mohammad, Khalid S., Guise, Theresa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352410/
https://www.ncbi.nlm.nih.gov/pubmed/28039445
http://dx.doi.org/10.18632/oncotarget.14139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352410/
https://www.ncbi.nlm.nih.gov/pubmed/28039445
http://dx.doi.org/10.18632/oncotarget.14139

Ejemplares similares